The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 10, 2020
Filed:
Jun. 01, 2015
Genecentric Therapeutics, Inc., Durham, NC (US);
The University of North Carolina AT Chapel Hill, Chapel Hill, NC (US);
Hawazin Faruki, Durham, NC (US);
Myla Lai-Goldman, Durham, NC (US);
Gregory Mayhew, Durham, NC (US);
Charles Perou, Carrboro, NC (US);
David Neil Hayes, Chapel Hill, NC (US);
Cheng Fan, Chapel Hill, NC (US);
Mark Miglarese, Durham, NC (US);
GeneCentric Therapeutics, Inc., Durham, NC (US);
The University of North Carolina at Chapel Hill, Chapel Hill, NC (US);
Abstract
Methods and compositions are provided for the molecular subtyping of lung cancer samples. Specifically, a method of assessing whether a patient's lung cancer subtype is adenocarcinoma, squamous cell carcinoma, or a neuroendocrine (encompassing both small cell carcinoma and carcinoid) is provided herein. A method for assessing whether a patient's lung cancer subtype is adenocarcinoma, squamous cell carcinoma, small cell carcinoma or carcinoid lung cancer is also provided. The methods provided herein entail probing the levels of the classifier biomarkers of Table 1-Table 6 or a subset thereof at the nucleic acid level, in a lung cancer sample obtained from the patient. Based in part on the levels of the classifier biomarkers, the lung cancer sample is classified as a particular lung cancer subtype.